대상포진 백신 시장 : 세계 예측(2026-2032년)

The Shingles Vaccine Market is projected to grow by USD 10.55 billion at a CAGR of 12.24% by 2032.

Shingles, or herpes zoster, is caused by reactivation of the varicella-zoster virus and is strongly associated with aging and immune compromise. The public health burden is material because shingles can lead to postherpetic neuralgia, ophthalmic complications, hospitalization, and prolonged quality-of-life impairment, particularly among adults aged 50 years and older and immunocompromised populations. Recombinant zoster vaccine has reshaped prevention strategies by demonstrating high efficacy in older adults and by enabling broader policy focus on adult immunization, life-course vaccination, and risk-based protection. Demand drivers in the shingles vaccine landscape include rising aging populations, expanded adult vaccination guidelines, improved awareness of postherpetic neuralgia prevention, and stronger pharmacy-based vaccine delivery. Health authorities in multiple countries recommend shingles vaccination for older adults, while select jurisdictions also prioritize immunocompromised adults, creating a more structured and prevention-oriented shingles vaccine ecosystem.

Transformative Shifts in the Shingles Vaccine Landscape

The shingles vaccine landscape is undergoing a structural shift from episodic adult vaccination toward planned, guideline-driven immunization. Healthcare systems are increasingly recognizing shingles prevention as part of healthy aging, supported by demographic trends showing rapid growth in populations aged 50 years and above. A second major shift is the move from legacy live-attenuated approaches toward recombinant, non-live vaccination strategies, which are suitable for a wider range of adults, including many immunocompromised individuals where clinically indicated by national guidance. Delivery is also changing as pharmacies, primary care networks, occupational health programs, and public health campaigns improve access beyond traditional physician-only settings. Digital reminder systems, electronic health records, and immunization registries are reducing missed opportunities by identifying eligible adults and prompting two-dose completion. Policy momentum is strongest where reimbursement, clinician recommendation, and public awareness align; in contrast, access gaps persist in regions with limited adult immunization infrastructure, out-of-pocket payment barriers, and weaker surveillance of adult vaccine uptake.

Cumulative Impact of Artificial Intelligence on Shingles Vaccination

Artificial intelligence is becoming an operational enabler across shingles vaccine research, access, delivery, and safety monitoring. In clinical and real-world evidence settings, AI-enabled analytics can help identify high-risk cohorts by combining age, immunosuppression status, comorbidities, medication histories, and healthcare utilization patterns. In public health operations, predictive models can support outreach prioritization, appointment scheduling, inventory planning, and two-dose adherence programs while minimizing wastage and improving clinic throughput. Natural language processing can assist pharmacovigilance by screening adverse event narratives, scientific literature, and safety databases for patterns requiring expert review. AI-driven patient engagement tools also support personalized education about shingles risk, vaccine timing, and series completion, though their use must be governed by privacy, transparency, equity, and clinical validation standards. The cumulative impact is not a replacement of clinical decision-making but a measurable improvement in targeted adult immunization, risk stratification, service efficiency, and evidence generation when deployed within regulated healthcare workflows.

Key Regional Insights for Shingles Vaccine Adoption

North America demonstrates the most mature adult shingles vaccination infrastructure, supported by established recommendations for older adults and, in the United States, guidance that includes adults aged 19 years and older who are or will be immunodeficient or immunosuppressed because of disease or therapy. Canada also maintains structured adult immunization guidance, though implementation varies by province and territory. Europe shows broad policy engagement through national immunization technical advisory processes, with countries such as the United Kingdom, Germany, France, Italy, and Spain progressively integrating shingles vaccination into age-based and risk-based programs; however, eligibility ages, reimbursement, and catch-up policies differ across health systems. Asia-Pacific is characterized by high unmet need due to rapid population aging in Japan, China, South Korea, Australia, and parts of Southeast Asia, with policy development advancing at different speeds and access influenced by regulatory approvals, local recommendations, and reimbursement maturity. Latin America is gaining relevance as countries strengthen adult immunization platforms, yet uptake depends heavily on public-sector prioritization, private healthcare access, and affordability. The Middle East is seeing increased attention to adult vaccines through preventive health reforms and expanding private-sector delivery, particularly in Gulf health systems. Africa remains at an earlier stage for shingles vaccination adoption because infectious disease priorities, funding constraints, and limited adult immunization infrastructure shape public health resource allocation, although urban private healthcare channels and aging demographics may gradually support targeted access.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN reflects a diverse shingles vaccine environment in which Singapore and higher-income urban healthcare markets are better positioned for adult vaccination access, while other member states face affordability, awareness, and infrastructure constraints. The GCC is increasingly aligned with preventive healthcare and life-course immunization objectives, with stronger potential for adult vaccine integration through centralized health systems, digital health records, and expanding private care. The European Union benefits from coordinated regulatory oversight and strong pharmacovigilance capacity, but vaccination policy remains nationally determined, leading to differences in eligibility, financing, and campaign intensity across member states. BRICS countries represent a heterogeneous opportunity profile: China and India have large aging populations and expanding healthcare access but variable adult immunization awareness, Brazil has experience with national vaccination infrastructure, Russia maintains centralized public health capacity, and South Africa faces competing healthcare priorities. G7 countries generally show stronger adult immunization policy frameworks, higher clinician awareness, and better reimbursement mechanisms, making them important reference markets for evidence-based shingles prevention strategies. NATO membership overlaps heavily with high-income North American and European health systems where adult vaccine security, resilient supply chains, and public health preparedness are increasingly emphasized, although defense alliance status itself does not determine vaccine policy.

Key Country Insights for Shingles Vaccine Strategies

The United States has one of the clearest shingles vaccine recommendation frameworks, with routine vaccination for adults aged 50 years and older and risk-based recommendations for immunocompromised adults aged 19 years and older, supported by pharmacy access and immunization information systems. Canada emphasizes adult immunization through national guidance, while provincial and territorial funding decisions affect patient access. Mexico and Brazil are building relevance through aging populations and private healthcare demand, though broad public funding for shingles vaccination is more limited than for pediatric and high-priority infectious disease vaccines. The United Kingdom has a structured national shingles immunization program with age-based eligibility and ongoing program updates, while Germany, France, Italy, and Spain rely on national or regional recommendations that increasingly recognize older adults and immunocompromised groups. Russia's opportunity is shaped by centralized healthcare governance and demographic aging, although public prioritization varies. China has substantial long-term need due to the scale of its older adult population and increasing availability of adult vaccines in urban settings, while India's large aging base, expanding private healthcare sector, and improving adult preventive care awareness create gradual demand development. Japan is highly relevant because of its super-aged population and strong healthcare access, and Australia maintains established immunization decision pathways with adult vaccine recommendations and public health evaluation mechanisms. South Korea combines rapid aging, high healthcare utilization, and digital health capabilities, supporting stronger adult vaccination outreach where reimbursement and guideline alignment are favorable.

Actionable Recommendations for Shingles Vaccine Industry Leaders

Industry leaders should prioritize evidence-based adult immunization strategies that address awareness, access, adherence, and equity without relying on pediatric vaccine playbooks. First, stakeholders should strengthen clinician education on shingles complications, postherpetic neuralgia prevention, and eligibility criteria for older and immunocompromised adults. Second, health systems should use electronic health records, pharmacy systems, and immunization registries to identify eligible patients and improve completion of multi-dose schedules. Third, public health planners should reduce access barriers through reimbursement clarity, pharmacy administration, community-based outreach, and integration with routine adult health visits. Fourth, communications should be tailored to older adults, caregivers, and immunocompromised patients using clear risk-benefit language aligned with national guidance. Fifth, leaders should invest in real-world evidence programs that evaluate vaccine uptake, series completion, safety, effectiveness, and disparities across socioeconomic and geographic groups. Finally, supply chain resilience, cold-chain reliability, and demand planning should be strengthened to support consistent access during seasonal healthcare pressures and broader immunization campaigns.

Research Methodology for Evidence-Based Shingles Vaccine Analysis

This executive summary is developed using secondary research and evidence synthesis from verified public health and scientific sources, including national immunization guidelines, regulatory communications, peer-reviewed medical literature, epidemiological publications, and public health agency materials. The methodology emphasizes triangulation across clinical evidence, policy recommendations, demographic indicators, vaccine delivery models, and real-world implementation trends. Regional, group, and country insights are interpreted through documented factors such as age-based eligibility, immunocompromised population guidance, reimbursement structures, adult immunization infrastructure, pharmacy access, surveillance systems, and public health prioritization. The analysis excludes market sizing, market share, commercial forecasts, and company-level positioning to maintain a policy- and evidence-focused perspective. Findings are reviewed for consistency with established clinical understanding of herpes zoster, including the relationship between aging, immune status, shingles incidence, and complication risk.

Conclusion: Advancing Shingles Prevention Through Adult Immunization

Shingles vaccination is becoming a core component of adult preventive healthcare as aging populations, immunocompromised patient needs, and the burden of postherpetic neuralgia intensify policy attention. The landscape is shifting toward recombinant vaccine strategies, guideline-based eligibility, pharmacy-enabled delivery, and data-supported outreach. Regional adoption remains uneven, with North America, parts of Europe, Japan, Australia, and South Korea showing stronger readiness, while Latin America, the Middle East, Africa, and parts of Asia-Pacific present access and infrastructure variability. Artificial intelligence can further improve patient identification, adherence, safety monitoring, and resource allocation when deployed responsibly. The most effective strategies will combine trusted clinical recommendations, equitable reimbursement, digital immunization tools, and sustained public education to improve shingles prevention outcomes across aging societies.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Shingles Vaccine Market, by Vaccine Type

• 7.1. Introduction
• 7.2. Recombinant Zoster Vaccine
• 7.3. Zoster Vaccine Live

8. Shingles Vaccine Market, by Dosage

• 8.1. Introduction
• 8.2. Multi Dose
• 8.3. Single Dose

9. Shingles Vaccine Market, by Age Group

• 9.1. Introduction
• 9.2. 50 To 59 Years
• 9.3. 60 To 69 Years
• 9.4. 70 Years And Above

10. Shingles Vaccine Market, by End User

• 10.1. Introduction
• 10.2. Clinics
  • 10.2.1. Community Clinics
  • 10.2.2. Private Clinics
• 10.3. Hospitals
  • 10.3.1. General Hospitals
  • 10.3.2. Specialty Hospitals

11. Shingles Vaccine Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Hospital Pharmacies
• 11.3. Online Pharmacies
• 11.4. Retail Pharmacies
  • 11.4.1. Chain Pharmacies
  • 11.4.2. Independent Pharmacies

12. Shingles Vaccine Market, by Region

• 12.1. Asia-Pacific
• 12.2. Europe
• 12.3. North America
• 12.4. Latin America
• 12.5. Africa
• 12.6. Middle East

13. Shingles Vaccine Market, by Group

• 13.1. NATO
• 13.2. G7
• 13.3. BRICS
• 13.4. European Union
• 13.5. ASEAN
• 13.6. GCC

14. Shingles Vaccine Market, by Country

• 14.1. China
• 14.2. United States
• 14.3. Japan
• 14.4. India
• 14.5. Germany
• 14.6. United Kingdom
• 14.7. Australia
• 14.8. France
• 14.9. South Korea
• 14.10. Italy
• 14.11. Canada
• 14.12. Russia
• 14.13. Brazil
• 14.14. Mexico
• 14.15. Spain

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. AbbVie Inc.
• 16.3. Amgen Inc.
• 16.4. AstraZeneca PLC
• 16.5. Baxter International Inc.
• 16.6. Biogen Inc.
• 16.7. Boehringer Ingelheim International GmbH
• 16.8. Bristol-Myers Squibb Company
• 16.9. Chiesi Farmaceutici S.p.A.
• 16.10. Cipla Limited
• 16.11. Daiichi Sankyo Co., Ltd.
• 16.12. Dr. Reddy's Laboratories Ltd.
• 16.13. Eagle Pharmaceuticals, Inc.
• 16.14. Eli Lilly and Company
• 16.15. EVER Pharma Jena GmbH
• 16.16. F. Hoffmann-La Roche Ltd.
• 16.17. Ferring B.V.
• 16.18. Fresenius SE & Co. KGaA
• 16.19. Gilead Sciences, Inc.
• 16.20. GlaxoSmithKline PLC
• 16.21. Glenmark Pharmaceuticals Limited
• 16.22. Johnson & Johnson Services, Inc.
• 16.23. Lupin Limited
• 16.24. Merck & Co., Inc.
• 16.25. Novartis AG
• 16.26. Novo Nordisk A/S
• 16.27. Pfizer Inc.
• 16.28. Sanofi S.A.
• 16.29. SCHOTT PHARMA AG & CO. KGAA
• 16.30. Sun Pharmaceutical Industries Limited
• 16.31. Teva Pharmaceutical Industries Ltd.
• 16.32. Viatris Inc.